The Edward R. Murrow Collection.

Bush, Gregory W.

doi:10.2307/2080981

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Resistance to β-lactam antibiotics mediated by bacterial β-lactamases (EC 3.5.2.6) is a global problem. , β-Lactamases hydrolyze and inactivate penicillins and cephalosporins, thereby rendering these β-lactams inactive before they reach their intended bacterial targets, the penicillin-binding proteins (PBPs). Hence, β-lactamases ensure bacterial survival against the therapeutic challenge of β-lactam antibiotics.…”

Section: Introductionmentioning

confidence: 99%

Rational Design of a β-Lactamase Inhibitor Achieved via Stabilization of the trans-Enamine Intermediate: 1.28 Å Crystal Structure of wt SHV-1 Complex with a Penam Sulfone

et al. 2006

View full text Add to dashboard Cite

Abstractβ-Lactamases are one of the major causes of antibiotic resistance in Gram negative bacteria. The continuing evolution of β-lactamases that are capable of hydrolyzing our most potent β-lactams presents a vexing clinical problem, in particular since a number of them are resistant to inhibitors. The efficient inhibition of these enzymes is therefore of great clinical importance. Building upon our previous structural studies that examined tazobactam trapped as a trans-enamine intermediate in a deacylation deficient SHV variant, a novel penam sulfone derivative was designed that forms a more stable trans-enamine intermediate. We report here the 1.28 Å resolution crystal structure of wt SHV-1 in complex with a rationally designed penam sulfone, SA2-13. The compound is covalently bound to the active site of wt SHV-1 similar to tazobactam, yet forms an additional salt-bridge with K234 and hydrogen bonds with S130 and T235 to stabilize the trans-enamine intermediate. Kinetic measurements show that SA2-13, once reacted with SHV-1 β-lactamase, is about 10 fold slower at being released from the enzyme compared to tazobactam. Stabilizing the trans-enamine intermediate represents a novel strategy for the rational design of mechanism-based class A β-lactamase inhibitors.

show abstract

Section: Introductionmentioning

confidence: 99%